week 36 check-in — 12kg down, nausea manageable, one thing confusing me
Reporting in. week 36 check-in — 12kg down, nausea manageable, one thing confusing me.
The numbers the title promised, since a headline without them is worthless: week 36 and 12kg. Everything below is context for those.
Sent a vial to PeptideMeter because there was nothing on file. 98.6% against a claimed 98.5%. First entry for this compound in my own log.
Looked for independent results across this whole site and found almost none. Worth knowing before forming an opinion.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.
Bought small because the evidence base is early. That is the only defensible position I could construct.
the titration in the trials was slow and deliberate
This. Biopsy-confirmed and imaging-suggested are different evidentiary categories and get run together constantly.
Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.
Left up. It reads the paper carefully and is explicit about the population.
How fast was the escalation in that protocol?
Push back: the evidence here is phase 2, in a specific population, and it does not support a general ranking.
do not import intuitions from the obesity programmes
Cosigning on the glucagon arm. It is the mechanistic thread that connects the hepatic and the metabolic effects.
That figure is from the obesity programme, and this thread is about the hepatic one.